Evidence map›Paper›PMID 23698643›Full record

GuidelineClinical pharmacology and therapeutics2013

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

S A Scott, K Sangkuhl, C M Stein, J-S Hulot, J L Mega, D M Roden, T E Klein, M S Sabatine, J A Johnson, A R Shuldiner and 1 more

2 registry-linked trialsOpen access · bronzeAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Clinical pharmacology and therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 433 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
433citing papers in PubMed, 17 pooled it
50.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05091879 nacompletednot on this mapstarted 2023, after this paper: background citation

Implementation and Evaluation of Preemptive Pharmacogenomics Testing in an Aging Population

TypeinterventionalSponsorGeisinger ClinicRan2023 to 2026Enrolled66ConditionsPolypharmacy, Pharmacogenomic TestingArmsMultigene pharmacogenomics test
NCT05763862 naactive not recruitingnot on this mapstarted 2023, after this paper: background citation

Genotype Guided Antiplatelet Therapy In Ischemic Stroke

TypeinterventionalSponsorNational Neuroscience InstituteRan2023 to 2026Enrolled350ConditionsIschemic Stroke, Transient Ischemic AttackArmsGenetic testing
3 · Its place in the literature

Who cites it

433 citing papers in PubMed, 17 syntheses or guidelines pooled it, 952 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Pooled it
  12. The role ofExpert review of clinical pharmacology · 2022
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Trial

373 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

S A ScottDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
K Sangkuhl
C M Stein
J-S Hulot
J L Mega
D M Roden
T E Klein
M S Sabatine
J A Johnson
A R Shuldiner
Clinical Pharmacogenetics Implementation Consortium
Icahn School of Medicine at Mount Sinai · USStanford University · USVanderbilt University · USAmerican Association of Colleges of Pharmacy · USBrigham and Women's Hospital · USThrombolysis in Myocardial Infarction Study Group · USUniversity of Maryland, Baltimore · US

Funding

PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2M
PHARMACOGENOMICS OF ARRHYTHMIA THERAPYU01HL065962 · NHLBI · VANDERBILT UNIVERSITY · PI RODEN, DAN M · 2001 to 2009
$24.8M
Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2005 to 2014
$20.7M
Pharmacogenomics of Arrhythmia TherapyU19HL065962 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2010 to 2014
$17.4M
Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) StudyU01HL105198 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2010 to 2014
$13.6M
PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9M
Mount Sinai Institutes for Clinical and Translational SciencesKL2TR000069 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SAMPSON, HUGH A · 2012 to 2014
$2.3M
NCATS NIH HHS KL2 TR000069NCATS NIH HHS KL2TR000069NHLBI NIH HHS U01 HL065962NHLBI NIH HHS U01 HL105198NHLBI NIH HHS U01HL105198NHLBI NIH HHS U01HL65962NHLBI NIH HHS U19 HL065962NHLBI NIH HHS U19HL065962-10NIGMS NIH HHS R24 GM061374NIGMS NIH HHS R24GM61374NIGMS NIH HHS U01 GM074492NIGMS NIH HHS U01GM074492NIGMS NIH HHS U01 GM092666NIGMS NIH HHS U01GM92666
6 · The paper itself

Abstract

Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Guideline updates include emphasis on appropriate indication for CYP2C19 genotype-directed antiplatelet therapy, refined recommendations for specific CYP2C19 alleles, and additional evidence from an expanded literature review (updates at http://www.pharmgkb.org).

Indexed as

Aryl Hydrocarbon HydroxylasesClopidogrelCytochrome P-450 CYP2C19Genetic TestingGenetic VariationGenotypeHumansPlatelet Aggregation InhibitorsRisk AssessmentTiclopidineAryl Hydrocarbon HydroxylasesClopidogrelCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsTiclopidine

Identifiers

PMID23698643
PMCPMC3748366
OpenAlexW2030352776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.